CLAIMS

1. Use of N-carbamimidoyl-5-(1-methyl-1H-pyrazol-4-yl)-2-naphthamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of influenza virus infection.

2. The use of claim 1, wherein replication of the influenza virus is inhibited.

3. The use of claim 1 or claim 2, wherein severity, intensity, or duration of complications or symptoms associated with the influenza virus infection are reduced.

4. The use of any one of claims 1 to 3, wherein the titre of the influenza virus is reduced.

5. The use of any one of claim 1 to 4, wherein the influenza virus is selected from influenza A virus, influenza B virus and influenza C virus.

6. The use of any one of claims 1 to 5, wherein the influenza virus is influenza A virus.

7. The use of claim 6 wherein the influenza A virus is selected from H1N1, H1N2, H2N2, H3N2, H3N8, H5N1, H5N2, H5N3, H5N6, H5N8, H5N9, H7N1, H7N2, H7N3, H7N4, H7N7, H7N9, H9N2, and H10N7 subtypes.

8. The use of claim 6 or claim 7, wherein the influenza A virus is selected from H1N1, H3N2 and H5N1 subtypes.

9. The use of any one of claims 1 to 5, wherein the influenza virus is influenza B virus.

10. The use of any one of claims 1 to 9, wherein the N-carbamimidoyl-5-(1-methyl-1H-pyrazol-4-yl)-2-naphthamide, or a pharmaceutically acceptable salt thereof, is to be administered by a route selected from oral, nasal, intravenous, intraperitoneal, inhalation and topical.

11. The use of any one of claims 1 to 10, wherein the N-carbamimidoyl-5-(1-methyl-1H-pyrazol-4-yl)-2-naphthamide, or a pharmaceutically acceptable salt thereof, is to be administered orally.

12. The use of any one of claims 1 to 11, wherein the N-carbamimidoyl-5-(1-methyl-1H-pyrazol-4-yl)-2-naphthamide, or a pharmaceutically acceptable salt thereof, is to be administered at a dosage of about 100mg to about 600mg.

13. The use of any one of claims 1 to 12, wherein the N-carbamimidoyl-5-(1-methyl-1H-pyrazol-4-yl)-2-naphthamide, or a pharmaceutically acceptable salt thereof, is to be administered orally, once daily at a dosage of about 100mg to about 200mg.

14. The use of any one of claims 1 to 12, wherein the N-carbamimidoyl-5-(1-methyl-1H-pyrazol-4-yl)-2-naphthamide, or a pharmaceutically acceptable salt thereof, is to be administered orally, twice daily at a dosage of about 100mg to about 200mg.

15. The use of any one of claims 1 to 14, wherein the N-carbamimidoyl-5-(1-methyl-1H-pyrazol-4-yl)-2-naphthamide, or a pharmaceutically acceptable salt thereof, is to be administered in combination with one or more additional antiviral agents preferably selected from zanamivir, oseltamivir and peramivir.